Aisling Capital Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Aisling Capital Management’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,600	Closed	-$16K	–	19
2022 Q2	$16K	Sell	3,600 -4,041	-53%	-$26.4K	0.01%	19
2022 Q1	$80K	Hold	7,641	–	–	0.04%	21
2021 Q4	$114K	Hold	7,641	–	–	0.04%	21
2021 Q3	$227K	Hold	7,641	–	–	0.05%	21
2021 Q2	$258K	Hold	7,641	–	–	0.04%	21
2021 Q1	$317K	Hold	7,641	–	–	0.06%	15
2020 Q4	$462K	Hold	7,641	–	–	0.08%	16
2020 Q3	$1.02M	Hold	7,641	–	–	0.33%	15
2020 Q2	$1.29M	Hold	7,641	–	–	0.49%	12
2020 Q1	$1.1M	Hold	7,641	–	–	0.48%	13
2019 Q4	$2.52M	Hold	7,641	–	–	0.97%	12
2019 Q3	$3.82M	Buy	7,641 +404	+6%	+$228K	1.99%	9
2019 Q2	$4.4M	Hold	7,237	–	–	1.88%	11
2019 Q1	$4.42M	Hold	7,237	–	–	3.36%	9
2018 Q4	$2.64M	Buy	+7,237	New	+$3.89M	2.78%	11

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aisling Capital Management's NBRV Position: Q3 2022 in Review

Aisling Capital Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2022, closing a stake of 3,600 shares — an estimated $16K sold.

Aisling Capital Management first reported a position in NBRV in Q4 2018 and held it in 15 quarters. The position peaked at $4.42M in Q1 2019. 13 funds tracked by Wall St. Rank hold NBRV as of Q3 2022.

Aisling Capital Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2022 after selling out during the quarter.
Aisling Capital Management sold 3,600 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2022, an estimated $16K.
Aisling Capital Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2018 and held it in 15 quarters.
Aisling Capital Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $4.42M in Q1 2019.
13 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2022.

Based on Aisling Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.